1. Academic Validation
  2. PD-1/PD-L1 pathway: current researches in cancer

PD-1/PD-L1 pathway: current researches in cancer

  • Am J Cancer Res. 2020 Mar 1;10(3):727-742.
Yanyan Han 1 Dandan Liu 2 Lianhong Li 1
Affiliations

Affiliations

  • 1 Pathology Department of Dalian Medical University Liaoning 116044, China.
  • 2 The Fourth Medical Center of The General Hospital of The Chinese People's Liberation Army Beijing 100048, China.
PMID: 32266087
Abstract

Cancer Immunotherapy has been accompanied by promising results over the past few years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating Apoptosis of antigen-specific T cells and inhibiting Apoptosis of regulatory T cells. Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce Apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells. Based on these perspectives, PD-1/PD-L1 axis is responsible for Cancer immune escape and makes a huge effect on Cancer therapy. This review is aimed to summarize the role of PD-1 and PD-L1 in Cancer, looking forward to improve the therapy of Cancer.

Keywords

PD-1; PD-L1; cancer.

Figures